as 04-23-2025 2:31pm EST
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Founded: | 2004 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 750.3M | IPO Year: | N/A |
Target Price: | $44.00 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.55 | EPS Growth: | N/A |
52 Week Low/High: | $3.25 - $14.44 | Next Earning Date: | 05-08-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AVXL Breaking Stock News: Dive into AVXL Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 hours ago
GuruFocus.com
2 days ago
GlobeNewswire
2 days ago
Simply Wall St.
16 days ago
Clinical Trials Arena
16 days ago
Benzinga
16 days ago
GlobeNewswire
18 days ago
GlobeNewswire
23 days ago
The information presented on this page, "AVXL Anavex Life Sciences Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.